1334419-91-8

Basic information

• Product Name: (6-bromo-1H-indazol-3-yl)-methyl-amine
• Synonyms: (6-bromo-1H-indazol-3-yl)-methyl-amine
• CAS NO: 1334419-91-8
• Molecular Weight: 226.076
• Mol File: 1334419-91-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (6-bromo-1H-indazol-3-yl)-methyl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (6-bromo-1H-indazol-3-yl)-methyl-amine(1334419-91-8)
• EPA Substance Registry System: (6-bromo-1H-indazol-3-yl)-methyl-amine(1334419-91-8)

Safety Data

• Hazardous Substances Data: 1334419-91-8(Hazardous Substances Data)

Upstream product

• 404827-77-6 ethyl 3-(3-(cyclopropanecarboxamido)-1H-indazol-6-yl)benzoate 
• 749927-69-3 4-bromo-2-fluoro-N-methylbenzanamide 

Downstream Products

• 1334419-60-1 N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(3-(methylamino)-1H-indazol-6-yl)benzamide 

Relevant articles and documents

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19

The Mediator complex-associated cyclin-dependent kinase CDK8 has been implicated in human disease, particularly in colorectal cancer where it has been reported as a putative oncogene. Here we report the discovery of 109 (CCT251921), a potent, selective, and orally bioavailable inhibitor of CDK8 with equipotent affinity for CDK19. We describe a structure-based design approach leading to the discovery of a 3,4,5-trisubstituted-2-aminopyridine series and present the application of physicochemical property analyses to successfully reduce in vivo metabolic clearance, minimize transporter-mediated biliary elimination while maintaining acceptable aqueous solubility. Compound 109 affords the optimal compromise of in vitro biochemical, pharmacokinetic, and physicochemical properties and is suitable for progression to animal models of cancer.

N1/N2-Lactam Acetyl-CoA carboxylase inhibitors

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal

INDAZOLE COMPOUNDS AND THEIR USES

The present application relates to therapeutic organic compounds, compositions comprising an effective amount of a therapeutic organic compound; and methods for treating and preventing disease comprising administering and effective amount of a therapeutic organic compound to a subject in need thereof.